td-5108 and Arrhythmias--Cardiac

td-5108 has been researched along with Arrhythmias--Cardiac* in 4 studies

Trials

1 trial(s) available for td-5108 and Arrhythmias--Cardiac

Article	Year
Thorough QT/QTc Study Shows That a Novel 5-HT Clinical pharmacology in drug development, 2020, Volume: 9, Issue:8 Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; Case-Control Studies; Cisapride; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Indoles; Irritable Bowel Syndrome; Long QT Syndrome; Male; Morpholines; Moxifloxacin; Piperidines; Placebos; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists	2020

Article

Year

Thorough QT/QTc Study Shows That a Novel 5-HT

Clinical pharmacology in drug development, 2020, Volume: 9, Issue:8

Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Arrhythmias, Cardiac; Asian People; Benzamides; Case-Control Studies; Cisapride; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans; Indoles; Irritable Bowel Syndrome; Long QT Syndrome; Male; Morpholines; Moxifloxacin; Piperidines; Placebos; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists

2020

Other Studies

3 other study(ies) available for td-5108 and Arrhythmias--Cardiac

Article	Year
Voltage gated ion channels blockade is the underlying mechanism of BIMU8 induced cardiotoxicity. Toxicology letters, 2017, Aug-05, Volume: 277 BIMU8 is a 5-HT4 Topics: Action Potentials; Arrhythmias, Cardiac; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Calcium Channel Blockers; Calcium Channels, L-Type; Cardiotoxicity; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Heart Rate; HEK293 Cells; Humans; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Risk Assessment; Serotonin 5-HT4 Receptor Agonists; Transfection; Voltage-Gated Sodium Channel Blockers	2017
[Cardiac safety of cinitapride]. Gastroenterologia y hepatologia, 2010, Volume: 33, Issue:8 Topics: Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Benzamides; Cisapride; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Drug Interactions; Dyspepsia; Electrocardiography; Gastrointestinal Agents; Humans; Ketoconazole; Serotonin 5-HT2 Receptor Antagonists; Serotonin 5-HT4 Receptor Agonists	2010
The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities. Journal of pharmacological sciences, 2007, Volume: 105, Issue:2 The blocking effect of three 5-HT(4) agonists, cisapride, mosapride, and the newly discovered CJ-033466 on the human ether-a-go-go-related gene (hERG) channel was studied using a whole cell patch-clamp technique in HEK293 cells. Cisapride was found to be the most potent of the hERG blockers. CJ-033466 had the widest safety margin between its hERG blocking activity and 5-HT(4) agonism among the tested compounds. This suggests a lower clinical risk of cardiac arrhythmia in CJ-033466 compared with the other 2 agonists. Therefore, CJ-033466 has the potential to be a drug with higher therapeutic efficacy and less cardiac risk than both cisapride and mosapride. Topics: Aminopyridines; Arrhythmias, Cardiac; Benzamides; Cell Line; Cisapride; Electrophysiology; Ether-A-Go-Go Potassium Channels; Humans; Imidazoles; Inhibitory Concentration 50; Morpholines; Patch-Clamp Techniques; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists	2007